Narendiran Rajasekaran

Dr. Narendiran Rajasekaran

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2005 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
SSSamuel Solomon
Samuel Solomon
NRNarendiran Rajasekaran
Narendiran Rajasekaran
EJElvira Jeisy‐Walder
Elvira Jeisy‐Walder
SSScott B. Snapper
Scott B. Snapper
HIHarald Illges
Harald Illges
Autoantibodies in the form of immune complexes are known to be crucial mediators in initiating inflammation in a variety of autoimmune diseases. This has been well documented in the anti‐collagen II antibody‐induced arthritis animal model for a long time now. Recently, in the K/B × N mouse model (the F1 of the TCR‐transgenic KRN and the diabetic NOD mice), anti‐glucose‐6‐phosphate isomerase (GPI) autoantibodies have been shown to induce arthritis. Experimental work in the K/B × N model demonstrated key roles of autoantigenic immune complexes activating the alternative pathway of complement, the subsequent association with C5aR and FcγRIII‐mediated cell activation and production of the inflammatory cytokines IL‐1 and TNF‐α, finally leading to joint destruction. The presence of high amounts of inflammatory cytokines and matrix‐degrading proteases at sites of inflammation obviously put the cytokine‐producing macrophages as the next target for investigation in this model. Here, we show that mice depleted of macrophages by clodronate liposome treatment are completely resistant to K/B × N serum‐induced arthritis. Reconstituting clodronate liposome‐treated mice with macrophages from naive animals could reverse this resistance. Also, we found that deficiencies in the Wiskott‐Aldrich syndrome protein and CD40, which are both implicated in macrophage activation, chemotaxis and phagocytosis, are not essential in serum‐induced arthritis. Mast cell degranulation was seen in arthritogenic serum‐treated mice even in the absence of macrophages, possibly suggesting that mast cell degranulation/activation acts hierarchically before macrophages in the inflammatory cascade of anti‐GPI antibody‐induced arthritis.

1 May 2016 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
XZXing Zhao
Xing Zhao
CCCariad Chester
Cariad Chester
NRNarendiran Rajasekaran
Narendiran Rajasekaran
ZHZhixu He
Zhixu He
HKHolbrook E. Kohrt
Holbrook E. Kohrt
The dominant cancer treatment modalities such as chemotherapy, radiotherapy, and even targeted kinase inhibitors and mAbs are limited by low efficacy, toxicity, and treatment-resistant tumor subclones. Oncolytic viral therapy offers a novel therapeutic strategy that has the potential to dramatically improve clinical outcomes. Reovirus, a double-stranded benign human RNA virus, is a leading candidate for therapeutic development and currently in phase III trials. Reovirus selectively targets transformed cells with activated Ras signaling pathways; Ras genes are some of the most frequently mutated oncogenes in human cancer and it is estimated that at least 30% of all human tumors exhibit aberrant Ras signaling. By targeting Ras-activated cells, reovirus can directly lyse cancer cells, disrupt tumor immunosuppressive mechanisms, reestablish multicellular immune surveillance, and generate robust antitumor responses. Reovirus therapy is currently being tested in combination with radiotherapy, chemotherapy, immunotherapy, and surgery. In this review, we discuss the current successes of these combinatorial therapeutic strategies and emphasize the importance of prioritizing combination oncolytic viral therapy as reovirus-based treatments progress in clinical development. Mol Cancer Ther; 15(5); 767–73. ©2016 AACR.

1 November 2005 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GSGunther Spohn
Gunther Spohn
KSKatrin Schwarz
Katrin Schwarz
PMPatrik Maurer
Patrik Maurer
HIHarald Illges
Harald Illges
NRNarendiran Rajasekaran
Narendiran Rajasekaran
MBMartin F. Bachmann
Martin F. Bachmann
TNF-related activation-induced cytokine (TRANCE), also known as receptor activator of NF-κB ligand (RANKL), is the key molecule responsible for the bone loss observed in osteoporosis. Passive administration of osteoprotegerin, the soluble decoy receptor of TRANCE/RANKL, is efficient in blocking disease progression, but may not find widespread clinical use due to patient compliance problems and the expected high costs. In this study, we describe an efficient, safe, and potentially cost-effective active immunization strategy against TRANCE/RANKL. We show in mice that immunization with TRANCE/RANKL covalently linked to virus-like particles can overcome the natural tolerance of the immune system toward self proteins and produce high levels of specific Abs without the addition of any adjuvant. Serum Abs of immunized mice neutralized TRANCE/RANKL activity in vitro and were highly active in preventing bone loss in a mouse model of osteoporosis. Active immunization against TRANCE/RANKL was essentially reversible and did not produce any measurable immunosuppressive side effects, underscoring its potential as a new therapeutic approach to the treatment of human bone-degenerative disorders.

27 March 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CACamilla Kofoed Andersen
Camilla Kofoed Andersen
SKSangita Khatri
Sangita Khatri
JHJonas Hansen
Jonas Hansen
SSSofie Slott
Sofie Slott
RPRohith Pavan Parvathaneni
Rohith Pavan Parvathaneni
KAKira Astakhova
Kira Astakhova
Two types of single-walled carbon nanotubes (SWCNTs), HiPco- and carboxyl-SWCNT, are evaluated as drug carriers for the traditional anti-inflammatory drug methotrexate (MTX) and a small interfering RNA (siRNA) targeting NOTCH1 gene. The nanotubes are solubilized by PEGylation and covalently loaded with MTX. The coupling efficiency (CE%) of MTX is 77–79% for HiPco-SWCNT and 71–83% for carboxyl-SWCNT. siRNA is noncovalently attached to the nanotubes with efficiency of 90–97% for HiPco-SWCNT and 87–98% for carboxyl-SWCNT. Through whole body imaging in the second near-infrared window (NIR-II window, 1000–1700 nm), SWCNTs were found to be selectively accumulated in inflamed joints in a serum transfer mouse model. We further investigated the interactions of the siRNA/MTX loaded nanotubes with human blood and mice bone marrow cells. In human blood, both types of unloaded SWCNTs were associated with B cells, monocytes and neutrophils. Interestingly, loading with MTX suppressed SWCNTs targeting specificity to immune cells, especially B cells; in contrast, loading siRNA alone enhanced the targeting specificity. Loading both MTX and siRNA to carboxyl-SWCNT enhanced targeting specificity to neutrophils and monocytes but not B cells. The targeting specificity of SWCNTs can potentially be adjusted by altering the ratio of MTX and siRNA loaded. The combined results show that carbon nanotubes have the potential for delivery of cargo drugs specifically to immune cells involved in rheumatoid arthritis.

1 May 2015 in ImmunoTargets and Therapy
Verified
Journal Article
Open access
PDF file
HKHolbrook Kohrt
Holbrook Kohrt
NRNarendiran Rajasekaran
Narendiran Rajasekaran
CCCariad Chester
Cariad Chester
AYAtsushi Yonezawa
Atsushi Yonezawa
XZXing Zhao
Xing Zhao
The therapeutic efficacy of some anti-tumor monoclonal antibodies (mAbs) depends on the capacity of the mAb to recognize the tumor-associated antigen and induce cytotoxicity via a network of immune effector cells. This process of antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells is triggered by the interaction of the fragment crystallizable (Fc) portion of the mAb with the Fc receptors on effector cells like natural killer cells, macrophages, γδ T cells, and dendritic cells. By augmenting ADCC, the antitumor activity of mAbs can be significantly increased. Currently, identifying and developing therapeutic agents that enhance ADCC is a growing area of research. Combining existing tumor-targeting mAbs and ADCC-promoting agents that stimulate effector cells will translate to greater clinical responses. In this review, we discuss strategies for enhancing ADCC and emphasize the potential of combination treatments that include US Food and Drug Administration-approved mAbs and immunostimulatory therapeutics.

24 February 2024 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
NRNarendiran Rajasekaran
Narendiran Rajasekaran
XWXiaoguang Wang
Xiaoguang Wang
SRSruthi Ravindranathan
Sruthi Ravindranathan
DCDaniel J Chin
Daniel J Chin
STSu-Yi Tseng
Su-Yi Tseng
SKSanjay D Khare
Sanjay D Khare
Over the past decade, US Food and Drug Administration (FDA)-approved immune checkpoint inhibitors that target programmed death-1 (PD-1) have demonstrated significant clinical benefit particularly in patients with PD-L1 expressing tumors. Toripalimab is a humanized anti-PD-1 antibody, approved by FDA for first-line treatment of nasopharyngeal carcinoma in combination with chemotherapy. In a post hoc analysis of phase 3 studies, toripalimab in combination with chemotherapy improved overall survival irrespective of PD-L1 status in nasopharyngeal carcinoma (JUPITER-02), advanced non-small cell lung cancer (CHOICE-01) and advanced esophageal squamous cell carcinoma (JUPITER-06). On further characterization, we determined that toripalimab is molecularly and functionally differentiated from pembrolizumab, an anti-PD-1 mAb approved previously for treating a wide spectrum of tumors. Toripalimab, which binds the FG loop of PD-1, has 12-fold higher binding affinity to PD-1 than pembrolizumab and promotes significantly more Th1- and myeloid-derived inflammatory cytokine responses in healthy human PBMCs in vitro. In an ex vivo system employing dissociated tumor cells from treatment naïve non-small cell lung cancer patients, toripalimab induced several unique genes in IFN-γ and immune cell pathways, showed different kinetics of activation and significantly enhanced IFN-γ signature. Additionally, binding of toripalimab to PD-1 induced lower levels of SHP1 and SHP2 recruitment, the negative regulators of T cell activation, in Jurkat T cells ectopically expressing PD-1. Taken together, these data demonstrate that toripalimab is a potent anti-PD-1 antibody with high affinity PD-1 binding, strong functional attributes and demonstrated clinical activity that encourage its continued clinical investigation in several types of cancer.